Works matching DE "CRIZOTINIB"

Results: 400

Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer.

Published in:

NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-023-00489-3

By:

Tan, Yan Qin;
Chiou, Yi-Shiou;
Guo, Hui;
Zhang, Shuwei;
Huang, Xiaoming;
Dukanya, Dukanya;
Kumar, Arun M.;
Basappa, Shreeja;
Liu, Suling;
Zhu, Tao;
Basappa, Basappa;
Pandey, Vijay;
Lobie, Peter E.

Publication type:

Article

BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study.

Published in:

NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-022-00341-0

By:

Nelson, Blessie Elizabeth;
Roszik, Jason;
Janku, Filip;
Hong, David S.;
Kato, Shumei;
Naing, Aung;
Piha-Paul, Sarina;
Fu, Siqing;
Tsimberidou, Apostolia;
Cabanillas, Maria;
Busaidy, Naifa Lamki;
Javle, Milind;
Byers, Lauren Averett;
Heymach, John V.;
Meric-Bernstam, Funda;
Subbiah, Vivek

Publication type:

Article

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling.

Published in:

NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00325-0

By:

Wang, Tiantian;
Wei, Li;
Lu, Qiang;
Shao, Yanmei;
You, Shuqing;
Yin, Jiani C.;
Wang, Sha;
Shao, Yang;
Chen, Zhanhong;
Wang, Zhe

Publication type:

Article

Disease progression patterns and molecular resistance mechanisms to crizotinib of lung adenocarcinoma harboring ROS1 rearrangements.

Published in:

NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00264-w

By:

Zhang, Yongchang;
Huang, Zhe;
Zeng, Liang;
Zhang, Xiangyu;
Li, Yizhi;
Xu, Qinqin;
Yang, Haiyan;
Lizaso, Analyn;
Xu, Chunwei;
Liu, Jun;
Wang, Wenxian;
Song, Zhengbo;
Ou, Sai-Hong Ignatius;
Yang, Nong

Publication type:

Article

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.

Published in:

NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00256-w

By:

Mansfield, A. S.;
Wei, Z.;
Mehra, R.;
Shaw, A. T.;
Lieu, C. H.;
Forde, P. M.;
Drilon, A. E.;
Mitchell, E. P.;
Wright, J. J.;
Takebe, N.;
Sharon, E.;
Hovelson, D.;
Tomlins, S.;
Zeng, J.;
Poorman, K.;
Malik, N.;
Gray, R. J.;
Li, S.;
McShane, L. M.;
Rubinstein, L. V.

Publication type:

Article

Exploring Novel ALK Inhibitors using Energy Based Pharmacophore Mapping and High-throughput Virtual Screening.

Published in:

Indian Journal of Pharmaceutical Education & Research, 2018, v. 52, n. 4, p. 707, doi. 10.5530/ijper.52.4.82

By:

James, Nivya;
Surana, Raunaq;
Thigale, Isha;
Preethi, B.;
Shanthi, V.;
Ramanathan, K.

Publication type:

Article

Advances in MET tyrosine kinase inhibitors in gastric cancer.

Published in:

Cancer Biology & Medicine, 2024, v. 21, n. 6, p. 484, doi. 10.20892/j.issn.2095-3941.2024.0044

By:

Yifan Zhang;
Lin Shen;
Zhi Peng

Publication type:

Article

Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.

Published in:

Cancer Biology & Medicine, 2018, v. 15, n. 2, p. 178, doi. 10.20892/j.issn.2095-3941.2018.0003

By:

Ling Zhang;
Yunxia Li;
Shaohong Zhang;
Chen Gao;
Keke Nie;
Youxin Ji

Publication type:

Article

Relevance of sun safety in patients commencing crizotinib for non‐small cell lung cancer.

Published in:

Australasian Journal of Dermatology, 2021, v. 62, n. 2, p. e332, doi. 10.1111/ajd.13503

By:

Heynemann, Sarah;
Mitchell, Paul

Publication type:

Article

Phenotypic variation of an ALK‐positive large‐cell neuroendocrine lung carcinoma with carcinoid morphology during treatment with ALK inhibitors.

Published in:

2018

By:

Hoton, Delphine;
Humblet, Yves;
Libbrecht, Louis

Publication type:

Case Study

Equivocal ALK fluorescence in-situ hybridization ( FISH) cases may benefit from ancillary ALK FISH probe testing.

Published in:

Histopathology, 2015, v. 67, n. 5, p. 654, doi. 10.1111/his.12708

By:

Selinger, Christina;
Cooper, Wendy;
Lum, Trina;
McNeil, Catriona;
Morey, Adrienne;
Waring, Paul;
Amanuel, Benhur;
Millward, Michael;
Peverall, Joanne;
Van Vliet, Chris;
Christie, Michael;
Tran, Yen;
Diakos, Connie;
Pavlakis, Nick;
Gill, Anthony J;
O'Toole, Sandra

Publication type:

Article

Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1234262

By:

Bole Li;
Shan Liu;
Honglei Feng;
Chunshuang Du;
Liman Wei;
Jie Zhang;
Guangwei Jia;
Chunnuan Wu

Publication type:

Article

Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1238009

By:

Yufan Huang;
Maojin You;
Qundan Wu;
Ruijia Chen

Publication type:

Article

Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.

Published in:

Frontiers in Pharmacology, 2023, p. 1, doi. 10.3389/fphar.2023.1212313

By:

Wei Chen;
Julian Miao;
Ying Wang;
Wenzhong Xing;
Xiumei Xu;
Rui Wu

Publication type:

Article

Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.

Published in:

Lung Cancer: Targets & Therapy, 2024, v. 15, p. 123, doi. 10.2147/LCTT.S467584

By:

Zhu, Jinlian;
Chen, Jie;
Liu, Wei;
Zhang, Junling;
Gu, Yulan

Publication type:

Article

Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.

Published in:

Lung Cancer: Targets & Therapy, 2020, v. 11, p. 19, doi. 10.2147/LCTT.S244366

By:

Mehta, Anurag;
Saifi, Mumtaz;
Batra, Ullas;
Suryavanshi, M;
Gupta, Kush

Publication type:

Article

Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.

Published in:

Lung Cancer: Targets & Therapy, 2019, v. 10, p. 87, doi. 10.2147/LCTT.S190786

By:

Facchinetti, Francesco;
Friboulet, Luc

Publication type:

Article

Targeting RET-rearranged non-small-cell lung cancer: future prospects.

Published in:

Lung Cancer: Targets & Therapy, 2019, v. 10, p. 27, doi. 10.2147/LCTT.S192830

By:

Bronte, Giuseppe;
Ulivi, Paola;
Verlicchi, Alberto;
Cravero, Paola;
Delmonte, Angelo;
Crinò, Lucio

Publication type:

Article

Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification.

Published in:

Lung Cancer: Targets & Therapy, 2019, v. 10, p. 21, doi. 10.2147/LCTT.S190403

By:

Zhu, Viola W;
Schrock, Alexa B;
Ali, Siraj M;
Ou, Sai-Hong Ignatius

Publication type:

Article

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer.

Published in:

Lung Cancer: Targets & Therapy, 2019, v. 10, p. 11, doi. 10.2147/LCTT.S179349

By:

Barrows, Stephanie M;
Wright, Kelly;
Copley-Merriman, Catherine;
Kaye, James A;
Chioda, Marc;
Wiltshire, Robin;
Torgersen, Knut Martin;
Masters, Elizabeth T

Publication type:

Article

Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALKpositive non-small cell lung cancer who are resistant or intolerant to crizotinib.

Published in:

Lung Cancer: Targets & Therapy, 2017, v. 8, p. 169, doi. 10.2147/LCTT.S126507

By:

Jain, Rohit K.;
Hongbin Chen

Publication type:

Article

Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives.

Published in:

Lung Cancer: Targets & Therapy, 2016, v. 7, p. 83, doi. 10.2147/LCTT.S99303

By:

Leprieur, Etienne Giroux;
Fallet, Vincent;
Cadranel, Jacques;
Wislez, Marie

Publication type:

Article

Severe Erosive Pill Esophagitis Induced by Crizotinib Therapy: A Case Report and Literature Review.

Published in:

Case Reports in Gastrointestinal Medicine, 2016, p. 1, doi. 10.1155/2016/3562820

By:

Jung, Patrick;
Fortinsky, Kyle J.;
Gallinger, Zane R.;
Tartaro, Piero

Publication type:

Article

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.

Published in:

Cancer Research & Treatment, 2018, v. 50, n. 3, p. 691, doi. 10.4143/crt.2017.280

By:

Makoto Nishio;
Dong-Wan Kim;
Yi-Long Wu;
Kazuhiko Nakagawa;
Solomon, Benjamin J.;
Shaw, Alice T.;
Satoshi Hashigaki;
Emiko Ohki;
Usari, Tiziana;
Paolini, Jolanda;
Polli, Anna;
Wilner, Keith D.;
Mok, Tony

Publication type:

Article

Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase - Positive Anaplastic Large Cell Lymphoma.

Published in:

Cancer Research & Treatment, 2018, v. 50, n. 2, p. 599, doi. 10.4143/crt.2016.357

By:

Wendan Xu;
Ji-Won Kim;
Woo June Jung;
Youngil Koh;
Sung-Soo Yoon

Publication type:

Article

Remarkable Response to Ceritinib and Brigatinib in an Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma Previously Treated with Crizotinib.

Published in:

2020

By:

Leroy, Laura;
Bonhomme, Benjamin;
Le Moulec, Sylvestre;
Soubeyran, Isabelle;
Italiano, Antoine;
Godbert, Yann

Publication type:

Letter

Efficient synthesis of the key chiral alcohol intermediate of Crizotinib using dual‐enzyme@CaHPO<sub>4</sub> hybrid nanoflowers assembled by mimetic biomineralization.

Published in:

Journal of Chemical Technology & Biotechnology, 2019, v. 94, n. 1, p. 236, doi. 10.1002/jctb.5769

By:

Chen, Xinxin;
Xu, Liqing;
Wang, Anming;
Li, Huimin;
Wang, Chenhui;
Pei, Xiaolin;
Zhang, Pengfei;
Wu, Stephen G

Publication type:

Article

Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer.

Published in:

American Journal of Case Reports, 2017, v. 18, p. 890, doi. 10.12659/AJCR.903528

By:

Dumont, Delphine;
Dô, Pascal;
Lerouge, Delphine;
Planchard, Gaëtane;
Riffet, Marc;
Dubos-Arvis, Catherine;
Danhier, Serge;
Gervais, Radj

Publication type:

Article

Predictive Evidence Threshold Scaling: Does the Evidence Meet a Confirmatory Standard?

Published in:

Statistics in Biopharmaceutical Research, 2018, v. 10, n. 2, p. 76, doi. 10.1080/19466315.2017.1392892

By:

Neuenschwander, Beat;
Roychoudhury, Satrajit;
Branson, Michael

Publication type:

Article

Exploring the crizotinib resistance mechanism of NSCLC with the L1196M mutation using molecular dynamics simulation.

Published in:

Journal of Molecular Modeling, 2017, v. 23, n. 11, p. 1, doi. 10.1007/s00894-017-3495-5

By:

Kay, Maryam;
Dehghanian, Fariba

Publication type:

Article

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.

Published in:

BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08746-z

By:

Beca, Jaclyn M.;
Walsh, Shaun;
Raza, Kaiwan;
Hubay, Stacey;
Robinson, Andrew;
Mow, Elena;
Keech, James;
Chan, Kelvin K. W.

Publication type:

Article

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.

Published in:

BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08746-z

By:

Beca, Jaclyn M.;
Walsh, Shaun;
Raza, Kaiwan;
Hubay, Stacey;
Robinson, Andrew;
Mow, Elena;
Keech, James;
Chan, Kelvin K. W.

Publication type:

Article

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.

Published in:

2021

By:

Beca, Jaclyn M.;
Walsh, Shaun;
Raza, Kaiwan;
Hubay, Stacey;
Robinson, Andrew;
Mow, Elena;
Keech, James;
Chan, Kelvin K. W.

Publication type:

journal article

Successful combination of crizotinib and hematopoietic stem cell transplantation in relapsed ALK-positive ALCL.

Published in:

2021

By:

Sun, Xue;
Fang, Xiaosheng;
Jiang, Yujie

Publication type:

Case Study

Ultra Performance Liquid Chromatography Tandem Mass Spectrometric Method Development and Validation for Determination of Neratinib in Human Plasma.

Published in:

South African Journal of Chemistry, 2015, v. 68, p. 93, doi. 10.17159/0379-4350/2015/v68a14

By:

Wani, Tanveer A.;
Zargar, Seema;
Ahmad, Ajaz

Publication type:

Article

KIF2C exerts an oncogenic role in nonsmall cell lung cancer and is negatively regulated by miR‐325‐3p.

Published in:

Cell Biochemistry & Function, 2019, v. 37, n. 6, p. 424, doi. 10.1002/cbf.3420

By:

Gan, Huizhu;
Lin, Lin;
Hu, Nanjun;
Yang, Yang;
Gao, Yu;
Pei, Yu;
Chen, Kang;
Sun, Butong

Publication type:

Article

The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.

Published in:

Pathology & Oncology Research, 2019, v. 25, n. 1, p. 217, doi. 10.1007/s12253-017-0332-1

By:

Felkai, Luca;
Bánusz, Rita;
Kovalszky, Ilona;
Sápi, Zoltán;
Garami, Miklós;
Papp, Gergő;
Karászi, Katalin;
Varga, Edit;
Csóka, Monika

Publication type:

Article

Reactive Oxygen Species (ROS)-Sensitive Prodrugs of the Tyrosine Kinase Inhibitor Crizotinib.

Published in:

Molecules, 2020, v. 25, n. 5, p. 1149, doi. 10.3390/molecules25051149

By:

Bielec, Bjoern;
Poetsch, Isabella;
Ahmed, Esra;
Heffeter, Petra;
Keppler, Bernhard K.;
Kowol, Christian R.

Publication type:

Article

Unexpected Rearrangement of N-Allyl-2-phenyl-4,5-Dihydrooxazole-4-Carboxamides to Construct Aza-Quaternary Carbon Centers.

Published in:

Molecules, 2019, v. 24, n. 24, p. 4495, doi. 10.3390/molecules24244495

By:

Choi, Goyeong;
Jo, Seoyoung;
Mun, Juyeon;
Jeong, Yonguk;
Kim, Seok-Ho;
Jung, Jong-Wha;
Garrido, Narciso M.

Publication type:

Article

Crizotinib-Associated Renal Cysts in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients: A Single-Center Experience.

Published in:

Urologia Internationalis, 2020, v. 104, n. 3-4, p. 269, doi. 10.1159/000502664

By:

Eiamprapaporn, Panuch;
Mungwatthana, Naphapatt;
Twinprai, Prin;
Sookprasert, Aumkhae;
Chindaprasirt, Jarin;
Ahooja, Anucha;
Watthanaudomrot, Sirinthip;
Sirithanaphol, Wichien

Publication type:

Article

Co-delivery of F7 and crizotinib by thermosensitive liposome for breast cancer treatment.

Published in:

Journal of Liposome Research, 2022, v. 32, n. 3, p. 265, doi. 10.1080/08982104.2021.2001499

By:

Li, Mingyuan;
Li, Yuan;
Li, Shiqin;
Jia, Lin;
Du, Chunyang;
Li, Meng;
Li, Shuangshuang;
Galons, Hervé;
Guo, Na;
Yu, Peng

Publication type:

Article

Mechanisms of Resistance to ALK-inhibitor Agents.

Published in:

Journal of OncoPathology, 2015, v. 3, n. 1, p. 67, doi. 10.13032/tjop.2052-5931.100115

By:

Frizziero, Melissa;
Tortora, Giampaolo;
Melisi, Davide

Publication type:

Article

Network pharmacology as a platform for drug discovery for hypertrophic scars.

Published in:

British Journal of Dermatology, 2024, v. 191, n. 4, p. 484, doi. 10.1093/bjd/ljae272

By:

Wang, Jennifer Y;
Kabakova, Margaret;
Austin, Evan;
Jagdeo, Jared

Publication type:

Article

Using network pharmacology to discover potential drugs for hypertrophic scars.

Published in:

British Journal of Dermatology, 2024, v. 191, n. 4, p. 592, doi. 10.1093/bjd/ljae234

By:

Zhang, Yi;
Li, Xiu;
Yu, Qian;
Lv, Xiaoyan;
Li, Chen;
Wang, Lianzhao;
Liu, Yue;
Wang, Qian;
Yang, Zhigang;
Fu, Xin;
Xiao, Ran

Publication type:

Article

Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1196211

By:

Yangjun Gu;
Min Xiao;
Zhitao Chen;
Qiyong Li

Publication type:

Article

Case Report: Long-term remission of malignant pleural and peritoneal effusion in a case of advanced lung adenocarcinoma treated with combined crizotinib and anlotinib therapy.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1191522

By:

Jin Tian;
Lin Long;
Jianhua Zang;
Peng Liu;
Lili Zhao;
Hongtao Zhang;
Jun Xiao

Publication type:

Article

Complete pathological response and negative postoperative ctDNA were not predictive of discontinuation of adjuvant crizotinib therapy in a patient with locally advanced MET ex14 skipping mutation-positive non-small cell lung cancer: a case report.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1164543

By:

Jiantao Wang;
Wenqing Yao;
Weiya Wang;
Mingyu Fan;
Kaili Huang;
Zhenkun Liu;
Daxing Zhu

Publication type:

Article

Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion.

Published in:

Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1169876

By:

Yun Shu;
Zhouyu Wang;
Hongjuan Shang;
Wei Le;
Yan Lei;
Longzhang Huang;
Liming Tao;
Jun Chen;
Jing Li

Publication type:

Article

Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib.

Published in:

Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1104910

By:

Xiaoqian Zhai;
Ting Wang;
Yiyun Lin;
Jiabi Zhang;
Yuqing Wang;
Weiya Wang;
Qinghua Zhou;
Daxing Zhu

Publication type:

Article

Case report: complete remission with crizotinib in ROS1 fusion-positive sinonasal mucosal melanoma.

Published in:

Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.942258

By:

Jun Cao;
Yaner Yu;
Yangkun Zhou;
Qing Ji;
Wenkang Qian;
Dongdong Jia;
Gu Jin;
Yajun Qi;
Xin Li;
Ningning Li;
Tao Li;
Meiyu Fang;
Hongchuan Jin

Publication type:

Article